The Ultimate 2020 Guide to Publicly Traded Psychedelic Stocks

For the latest updates and deepest insights on publicly traded psychedelic stocks and their dynamic impact on capital markets, make sure to attend Psychedelic Capital, the world’s premiere psychedelic due diligence conference. You can get free tickets to this dynamic event here!

While the Coronavirus pandemic may have brought forth unexpected chaos for the world in 2020, the psychedelic renaissance witnessed some historic victories. As the movement to medicalize these powerful medicines strengthen, capital markets are being overrun with an array of psychedelic stocks. The modern investor now has a wide variety of options for investing in burgeoning shroom stocks and supporting psychedelic science and research. This comprehensive blog will serve as the ultimate guide to publicly traded psychedelic stocks in 2020.

mindmed publicly traded psychedelic stock

MindMed (NEO: MMED)

Mind Medicine (MindMed) Inc., a neuro-pharmaceutical company, discovers, develops, and deploys psychedelic inspired medicines to improve health, promote wellness, and alleviate suffering. The company is primarily focusing on developing a non-hallucinogenic version of the psychedelic ibogaine to address the opioid crisis. It also has initiated or is initiating studies to evaluate potential treatments to help patients with adult attention deficit/hyperactivity disorder (ADHD), anxiety, cluster headaches, and substance abuse. The company is headquartered in New York, New York.

champignon brands publicly traded psychedelic stock

Champignon Brands Inc. (CSE: SHRM)

Champignon is focused on the formulation and manufacturing of novel ketamine, anaesthetics, and adaptogenic delivery platforms for nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The Company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability as its medicinal mushroom-infused SKUs are organic, non-GMO, and vegan certified.

compass pathways publicly traded psychedelic stock

Compass Pathways (NASDAQ: CMPS)

Being the first psychedelic stock to debut on the NASDAQ, Peter Thiel-backed powerhouse Compass Pathways has set an extraordinary precedent for the psychedelic medicine movement. Compass Pathways describes themselves as a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Their initial focus is on using psilocybin in conjunction with psychological support for treatment-resistant depression, or TRD, a subset of major depressive disorder (MDD). This is one of many subsets of severely underserved patients with mental illness. Currently, the team at Compass leads the way in research and development spending, setting a bold antecedent for the greater psychedelic movement.

Read: CMPS Stock Surges More Than 20% on the Back of Bullish Citron Research Report

Field Trip Health (CSE: FTRP)

Field Trip is a global leader in the development and delivery of psychedelic therapies. With Field Trip Discovery, the Company’s research division, leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics, Field Trip Health clinics for psychedelic therapies operating and opening within North America and Field Trip Digital, the Company’s technology division, building the digital and technological tools to support psychedelic experiences and consciousness expansion. The company has recently opened up their fourth psychedelic-enhanced therapy center in the heart of Chicago.

Read PsyCap Recap: 3 Key Takeaways from the Field Trip Health Presentation at Psychedelic Capital

Numinus Publicly Traded Psychedelic Stock

Numinus (TSXV: NUMI)


Numinus Wellness, Inc. is an integrated healthcare and R&D company creating an industry-leading ecosystem of solutions to support delivery of psychedelic-assisted psychotherapy. Numinus Bioscience is a first-in-country Health Canada-licensed lab for psychedelic substance research. Numinus R&D develops psychedelic-assisted therapeutic protocols to embed in mainstream health care, led by medical leadership with global research and policy reform experience. Numinus Health delivers treatments to patients through clinics and virtual services, for physical, mental, and emotional healing. The company has recently completed Canada’s very first legal psilocybin harvest–a monumental achievement. Their licensure also allows them to test, possess, buy, and sell MDMA, psilocybin, psilocin, DMT and mescaline. The company was founded by Payton Nyquvest and Stacey Wallin in 2018 and is headquartered in Vancouver, Canada. Microdose would like to thank Numinus for helping us spotlight inspirational voices in psychedelic medicine, such as Dr. Gabor Maté, in our upcoming documentary “The World on Drugs”. The team at Numinus is sure to have an impact on the landscape of publicly traded psychedelic stocks.

Read PsyCap Recap: 3 Key Takeaways From the Numinus Presentation at Psychedelic Capital

Cybin Corp psychedelic capital magic mushroom psilocybin

Cybin Corp (NEO: CYBN)


Having recently gone public on the heels of completing the largest ever go-public financing campaign for psychedelics in Canada, the team at Cybin Corp is poised to make a massive impact in the emerging psychedelic sector. Cybin Corp. engages in the research and development of psychedelic and medicinal products. The company offers medical mushroom-psilocybin extracts infused psychedelic medicines under the brand JOURNEY. It serves psychedelic, pharmaceutical, and nutraceutical sectors. The company was incorporated in 2019 and is based in Toronto, Canada. The dynamic world of publicly traded psychedelic stocks is witnessing the entry of a huge player in the game with CYBN.

Read PsyCap Recap: 3 Key Takeaways from the Cybin Corp Presentation at Psychedelic Capital

havn life psychedelic education

HAVN Life Sciences (CSE: HAVN)

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow them on Facebook, Twitter and Instagram. When exploring the world of psychedelic stocks, HAVN is definitely one company worth keeping an eye on. 


Read PsyCap Recap: 3 Key Takeaways from the Havn Life Presentation at Psychedelic Capital

Entheon Biomedical

Entheon Biomedical (CSE: ENBI)

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.   

Read The Entheon Approach: Using the Powerful Hallucinogen DMT for Opioid Addiction

better plant sciences

Better Plant Sciences (CSE: PLNT)

Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It has 14 patent applications to protect its Intellectual Property, and over 200 proprietary wellness formulas at various stages of commercialization, including over 20 proprietary products that are now for sale via eCommerce or brick-and-mortar retail stores. It operates websites and oversees eCommerce and Amazon sales for over 200 JUSU plant based products for body, baby and home. Its majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for a Section 56 Exemption to begin preclinical trials to study its pending psychedelic medicine patents.

Revive Therapeutics

Revive Therapeutics Ltd. (CSE: RVV)

Revive Therapeutics Ltd. is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.  Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza strains including COVID-19.  With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.  For more information visit www.ReviveThera.com.

m2bio

M2BIO (OTC: WUHN)

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx and Medspresso brands. In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies.

mind cure health

Mind Cure Health Inc. (CSE: MCUR)



Mind Cure is a mental health and wellness company with a mission to identify, develop and commercialize products that ease suffering, increase productivity, and enhance mental health. It is the therapeutic potential of nootropics, psychoactive products, and psychedelic substances to treat the profound distress of a world suffering from a mental health crises that led to the formation of Mind Cure. Mind Cure’s initial products are a branded line of organic mushroom nootropics.

Mydecine

Mydecine Innovations Group (CSE: MYCO)

Mydecine Innovations Group is a life sciences company dedicated to the development and commercialization of adaptive pathway medicines, natural health products and digital health solutions.

hollister biosciences

Hollister Biosciences (CSE: HOLL)



Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

new wave holdings corp

New Wave Holdings (CSE: SPOR)

New Wave Holdings is an investment issuer that provides capital and support services to multiple emerging industries, including esports and psychedelics. Recently, the team at New Wave Holdings sponsored the next phase of the upcoming Microdose documentary, “The World on Drugs”.

Lobe Sciences

Lobe Sciences (CSE: LOBE)

Lobe Sciences is a growth-oriented research, technology and services company focused on transformational medicines and devices.  Based in Vancouver, BC, Lobe Sciences Ltd. creates value through acquisitions and development of assets, products and technologies by leveraging its scientific, engineering, branding and operation expertise supported by strong capital markets acumen.  

thoughtful brands

Thoughtful Brands (CSE: TBI)

Thoughtful Brands Inc. is an eCommerce technology company that researches, develops, markets and distributes natural health products through various brands in North America and Europe. Through continuous strategic acquisitions, the Company has a strong footprint in the CBD market, as well as the burgeoning psychedelic medicine sector. Thoughtful Brands owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebeul, Germany, where its highly skilled team conducts clinical studies utilizing naturally occurring psilocybin and other compounds found in psychedelics for the treatment of opiate addiction, while planning for future opportunities to create proprietary psilocybin products.

Silo wellness

Silo Wellness (Coming Soon)



SILO was founded in Oregon and has been in the psychedelics and functional mushroom space since 2018 and ultimately formulated and announced a patent-pending psilocybin nasal spray in Jamaica in 2019. This metered-dosing delivery modality was created for consumer microdosing to address some of the primary issues that may prevent many from trying natural psychedelics for the first time, including dose reliability, taste, stomach upset, and stigma.   The nasal spray bypasses the digestive system by entering the bloodstream through the nasal membranes

Aion Therapeutic (CSE: AION)



Aion Therapeutic Inc.  is an early-stage cannabinoid extraction company based in Oliver, BC. Aion has applied for a standard processing license under the Cannabis Act for its 10,410 ft2 facility and that application is currently in the review stage. The Company will offer contract tolling extraction, sale of bulk oil and development of both proprietary Aion Cannabis branded and white labelled products once licensed to do so. Dr. Stephen Barnhill, who heads their clinical team, currently holds several patents on unique cannabis and mushroom formulations for a variety of indications.

Read PsyCap Recap: 3 Key Takeaways From Aion Therapeutic Inc.’s Psychedelic Capital Presentation

Ehave psychedelic capital presentation

Ehave Inc. (OTC: EHVVF)

Ehave, Inc. (OTCQB: EHVVF) is empowering the medical cannabis and mental healthcare community with a next generation of data-rich tools designed to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave’s mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems (“MHS”), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder (“ADHD”), through its collaboration with the Hospital for Sick Children (“SickKids”). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with leading medical cannabis licensed producers. www.ehave.com.


Read PsyCap Recap: 3 Key Takeaways from the Ehave Inc. Presentation at Psychedelic Capital

roadman investments corp

Roadman Investments Corp (TSXV: LITT)

Roadman Investments Corp. is a venture capital, private equity and advisory firm specializing in incubation, seed, later stage, strategic advisory, global partnership development, breakthrough products, devices, treatments, health supplement, corporate restructuring, Corporate recapitalization and growth capital investments. It focuses on managing and facilitating foreign investment and investing in private and public companies whose businesses involve later-stage. The firm prefers to invest in health & wellness, agricultural, strategic alliance, media, retail, medical device, financial services, pharmaceutical products, nutrition, medicine, technology, healthcare, clean tech, energy, consumer product, and consumer services and identify an exit strategy in China or North America. The firm invests into companies across the Pan-Pacific region. It prefers to take majority stake in its portfolio companies. They are sure to be a dynamic player in the world of psychedelic stocks!

Nova mentis life science corp

Nova Mentis (CNSX: NOVA)

Nova Mentis Life Science Corp. is a Canadian-based, public company whose focus is to build and support a diversified portfolio of health and wellness businesses. Key holdings include its wholly-owned subsidiary, Nova Mentis Biotech Corp., a R&D driven company primarily focused on exploring the anti-inflammatory effects of psilocybin in under-explored metabolic indications such as obesity, autism and diabetes. The team at Nova Mentis is about to acquire Pilz Biosciences and add the dynamic scientific team led by Dr. Marvin Hausman very soon! NOVA is sure to be one of many exciting psychedelic stocks that are entering the market. 

Read: Pilz Biosciences Advances Preclinical Research Investigating Psilocybin for Autism

code base ventures

Codebase Ventures (CSE: CODE)

Codebase Ventures is an investment firm offering investors a diverse portfolio of opportunities, including a direct stake in Red Light Holland, a publicly-traded entity involved in the psychedelic stocks market through its subsidiary Titan Shrooms & Psychedelics.

Pharmather

Pharmather (CSE: PHRM)

Pharmather is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. Pharmather was founded with a particular focus on repurposing psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval for the treatment of brain and nervous system disorders.

Pure Extracts Corp

Pure Extracts Corp (CSE: PULL)

Pure Extracts Technologies Corp. is an integrated Canadian plant-based extraction company specializing in the processing of cannabis, hemp and functional mushrooms to produce oils and various derivative products. The company is involved in white labeling activities as well as selling branded oil based products under the Pure Extracts brand.

 

Read PsyCap Recap: 3 Key Takeaways From the Pure Extracts Corp Presentation at Psychedelic Capital

Looking Ahead to the Dynamic World of Psychedelic Stocks & Capital Markets

As the emerging psychedelic medicine space continues to expand, so will the dynamic world of psychedelic capital. To get the deepest insights and latest updates from leading industry experts and thought leaders, make sure to attend our monthly Psychedelic due diligence conference, Psychedelic Capital. You can grab free tickets here! 

You can also subscribe to our weekly Market Insights Report email newsletter to get the latest scoop on psychedelic capital markets right at your fingertips. Additionally, for the latest updates on conferences, content and more, subscribe to the Monthly Microdose email newsletter!

Microdose Psychedelic Insights

Microdose Psychedelic Insights

Your Guide to the Business of Psychedelics. Our mission is to shift the world's perception of psychedelic medicine.